STERIS plc (NYSE:STE) Shares Sold by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC cut its stake in STERIS plc (NYSE:STE) by 25.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,959 shares of the medical equipment provider’s stock after selling 682 shares during the period. Prime Capital Investment Advisors LLC’s holdings in STERIS were worth $475,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Ashton Thomas Securities LLC purchased a new position in STERIS during the third quarter worth approximately $25,000. Central Pacific Bank Trust Division purchased a new position in shares of STERIS in the 3rd quarter worth $28,000. Quent Capital LLC boosted its holdings in STERIS by 112.7% in the first quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 71 shares during the last quarter. Headlands Technologies LLC purchased a new stake in STERIS during the first quarter valued at about $36,000. Finally, Versant Capital Management Inc increased its stake in STERIS by 2,262.5% during the second quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider’s stock worth $41,000 after acquiring an additional 181 shares during the last quarter. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

STERIS Stock Performance

STERIS stock opened at $220.12 on Friday. STERIS plc has a 12-month low of $195.47 and a 12-month high of $248.24. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 1.55. The company has a market capitalization of $21.73 billion, a price-to-earnings ratio of 50.26 and a beta of 0.85. The firm’s fifty day moving average price is $230.37 and its 200 day moving average price is $228.26.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.12 by $0.02. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The business had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.33 billion. During the same period in the previous year, the company earned $2.03 earnings per share. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. On average, research analysts forecast that STERIS plc will post 9.15 EPS for the current fiscal year.

STERIS Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 19th. Investors of record on Tuesday, November 19th will be paid a $0.57 dividend. The ex-dividend date is Tuesday, November 19th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.04%. STERIS’s dividend payout ratio (DPR) is presently 52.05%.

Wall Street Analyst Weigh In

STE has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research note on Friday, November 8th. StockNews.com cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 29th. JMP Securities reissued a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research report on Wednesday, August 7th. Piper Sandler upgraded shares of STERIS from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $230.00 to $260.00 in a report on Thursday, October 24th. Finally, Stephens reiterated an “overweight” rating and issued a $260.00 price target on shares of STERIS in a report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $253.00.

Insider Activity at STERIS

In other news, CFO Michael J. Tokich sold 23,332 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the sale, the chief financial officer now owns 42,930 shares of the company’s stock, valued at approximately $10,603,710. The trade was a 35.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.14% of the stock is currently owned by corporate insiders.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.